arrow
R

Rajeshri G. Karki

Novartis
H指数:21
被引数:1,820

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery of EGT710; an Oral Nonpeptidomimetic Reversible Covalent SARS-CoV-2 Main Protease Inhibitor

EGT710的发现:一种口服非肽类拟似可逆共价SARS-CoV-2主蛋白酶抑制剂

2026-02-090
PRE
Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes
2023-07-030
PRE
Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach
2020-06-1715
PREAI
Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases
2020-02-1943
PREAI
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors
2020-01-275
OAAI
Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders
2020-01-2023
PREAI
Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex (vol 85, pg 231, 2019)
2020-01-150
OAAI
Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
2019-12-09165
PREAI
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway
2019-04-1715
PREAI
Small-molecule factor B inhibitor for the treatment of complement-mediated diseases
2019-03-29153
OAAI
Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers
2018-10-19150
PREAI